Table 1.
Outcome Characteristics
| Immunotherapy (N = 504) | Chemotherapy (N = 2,214) | Oral Therapy (N = 2,747) | ||||
|---|---|---|---|---|---|---|
| Binary Outcome | Count | (%) | Count | (%) | Count | (%) |
| ER Visit in 60 Days | 22 | (4.4) | 182 | (8.2) | 100 | (3.6) |
| Count Outcome | Mean | (SD) | Mean | (SD) | Mean | (SD) |
| ER Visits in 180 Days | 0.13 | (0.44) | 0.23 | (0.79) | 0.12 | (0.50) |
| Time to Event Outcome (days) | Median | (Q1, Q3) | Median | (Q1, Q3) | Median | (Q1, Q3) |
| Time on Treatment1 | 227 | (29,638) | 110 | (43,338) | 224 | (83,462) |
| Longitudinally Varying Outcome | Count | (%) | Count | (%) | Count | (%) |
| Enrolled at 90 days | 438 | (87.0) | 1707 | (77.1) | 2235 | (81.4) |
| Enrolled at 180 days | 381 | (75.6) | 1353 | (61.1) | 1788 | (65.1) |
| Any Opioids Prescribed at Any Time | 166 | (32.9) | 936 | (42.3) | 1281 | (46.6) |
| Opioids at Baseline2 | 73 | (14.5) | 653 | (29.5) | 825 | (30.0) |
| Opioids at 90 Days | 87 | (19.9) | 427 | (25.0) | 578 | (25.9) |
| Opioids at 180 Days | 65 | (17.1) | 359 | (26.5) | 515 | (28.8) |
| Patients Prescribed (morphine milligram equivalents, 30-day supply) | Median | (Q1, Q3) | Median | (Q1, Q3) | Median | (Q1, Q3) |
| Opioids at Treatment Start | 112 | (39,435) | 241 | (75,1052) | 184 | (72,674) |
| Opioids 90 Days from Treatment Start | 87 | (73,871) | 427 | (87,1182) | 578 | (83,887) |
| Opioids 180 Days from Treatment Start | 391 | (97,895) | 406 | (89,1448) | 191 | (60,667) |
Table 1 shows outcome characteristics across the three treatment groups: immunotherapy (sipuleucel-T), chemotherapy (docetaxel), and oral therapy (enzalutamide or abiraterone). ER is an abbreviation for emergency room. Q1 denotes first quartile of distribution, and Q3 denotes third quartile.
1
Total time on treatment was defined as when the last of any focus treatment was recorded.
2
Opioids were identified from a list of generic brand names and converted into 30 day milligram morphine equivalents (MME) using the CDC compilation and conversion factors.